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Simple tuberculosis (TB) treatment monitoring tools are needed. We assessed the performance of fluorescein-diacetate (FDA)
smear microscopy for detection of viable Mycobacterium tuberculosis in sputum specimens (n 5 288) of TB cases under treat-
ment compared to culture (17.4% culture positivity). FDA sensitivity was moderate (83.7% [95% confidence interval {CI}, 70.3 to
92.6]), and specificity was low (66.1% [59.5 to 72.2]). The good negative predictive value (94.8% [90.1 to 97.8]) and negative like-
lihood ratio (0.2) suggest using this method to rule out treatment failure in settings without access to culture.
Monitoring the response to tuberculosis (TB) treatment is es-sential to detect failure or drug resistance early (12). The
only monitoring tool available in resource-limited settings is spu-
tum smear microscopy using Ziehl-Neelsen (ZN) or auramine
staining (11, 12). Smear positivity at month 3 or later should be
investigated with Mycobacterium tuberculosis culture and drug
susceptibility testing (DST), while smear positivity at month 5 or
later defines treatment failure (12). Importantly, smear micros-
copy cannot distinguish viable from dead bacilli. A significant
proportion of patients on treatment may, however, continue to
cough up dead bacilli from necrotic lung cavities, thus remaining
“smear positive” although responding to therapy (1, 5, 8, 9, 10,
12). These patients are at risk of receiving an unnecessary pro-
longed or new treatment regimen in settings with limited or no
access to M. tuberculosis culture. Culture is the only test that can
identify viable bacilli, but it requires several weeks to report results
and needs a high level of expertise and laboratory infrastructure.
Recent studies proposed a simple and instant method for TB treat-
ment monitoring, based on a common fluorescent viability
marker, fluorescein-diacetate (FDA) (4), in combination with
smear microscopy (2, 3).
We assessed the performance of the FDA vital staining method
compared to M. tuberculosis culture in a peripheral smear micros-
copy laboratory in Mae Sot, Thailand. Sputum specimens were
collected during routine TB treatment monitoring from pulmo-
nary TB cases at months 2, 3 (if positive at month 2), 5, and 6 for
treatment of new TB cases and at months 3, 4 (if positive at month
3), 5, and 8 for treatment of previously treated TB cases. Two
consecutive specimens per time point were processed by the stan-
dard direct Ziehl-Neelsen (ZN) smear microscopy (11). Only ZN-
positive specimens were included in the study and were subjected
to FDA smear microscopy within a median of 2 days upon speci-
men collection according to published FDA procedures (2). FDA
stock solution (FDA F1303 [Molecular Probes, Inc.], 25 mg/ml in
acetone, stored at 220°C) was used to prepare fresh staining so-
lution (0.5 mg/ml) in phosphate-buffered saline (pH 7.3, Dul-
becco A BR0014 [Oxoid Ltd.], with 0.05% Tween 80). After air
drying, FDA smears were examined by fluorescence microscopy at
31,000 magnification using an Olympus CX21 microscope
equipped with a FluoLedBlue (480-nm) light-emitting diode
(LED) cassette (Fraen Corporation Srl, Italy) and a 535/40-nm
band-pass filter. An FDA-positive (FDA1) smear was defined by
at least 1 fluorescent bacillus/100 high-power fields (11). The re-
maining specimen was sent for M. tuberculosis culture at the In-
ternational Organization for Migration (IOM) laboratory in Mae
Sot. Specimen decontamination used N-acetyl-L-cysteine-sodium
hydroxide, with a 2% NaOH final volume concentration for 15
min. One liquid Bactec MGIT 960 and two solid egg-based Low-
enstein-Jensen cultures were inoculated per specimen. Positive
cultures were tested by ZN smear, and identification of M. tuber-
culosis species versus nontuberculous mycobacteria (NTM) was
performed by the rapid nucleic acid hybridization method (Gen-
Probe Accuprobe Mycobacterium tuberculosis complex culture
identification test; Biogenentech). A specimen was defined as
“contaminated” if all 3 culture media were contaminated, “M.
tuberculosis positive” if $1 of 3 cultures was positive, and “M.
tuberculosis negative” otherwise. Unreadable FDA smears and
culture-contaminated or NTM-positive specimens were excluded
from the performance analysis. The study was approved by the
Comité de Protection des Personnes, Saint Germain en Laye,
France, and the Ethical Review Committee of the Ministry of Pub-
lic Health, Thailand.
Two hundred eighty-eight ZN1 specimens from 215 treatment
follow-up cases were included between December 2007 and
March 2009. Of them, 77.4% were scanty ZN positive (i.e., with 1
to 9 bacilli/100 high power fields [HPF]) and 69.1% were derived
from the end of the intensive phase or the end of the prolonged
intensive phase of treatment (“delayed treatment responder spec-
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imens”) (Fig. 1). Among the total 288 specimens, 50 (17.4%) were
M. tuberculosis culture positive, 13 (4.5%) were NTM positive, 224
(77.8%) were culture negative, and 1 (0.3%) was contaminated. In
total, 125 (43.4%) of specimens were FDA smear positive, and 100
(80%) of these were scanty positive. The sensitivity of FDA smear
was 83.7%, and its specificity was 66.1% (Table 1). False-positive
FDA results were significantly more frequent among scanty FDA-
positive results (67/93, 72%) than among highly positive FDA
results ($11) (9/24, 37.5%), with a P value of 0.002 (Wald test).
The negative predictive value (NPV) was 94.8%, and the negative
likelihood ratio (LR2) was 0.2 (Table 1). A subset performance
analysis by treatment phase indicated a significantly higher spec-
ificity among specimens from suspected treatment failures than
among specimens from delayed treatment responders (P 5 0.011,
Wald test) (Table 1).
The overall performance of FDA was lower than previously
reported (2). This may be explained by notable differences in the
study populations. Hamid et al. included exclusively specimens
from suspected failure cases, which were largely culture positive
(61.4%) and mainly with high acid-fast bacillus (AFB) loads (80%
with scores of $11). The present study population was charac-
terized by mostly scanty ZN-positive specimens from delayed
treatment responders with a low culture positivity rate. Indeed,
the FDA accuracy seemed lower in paucibacillary specimens. Fur-
thermore, FDA specificity may have been underestimated due to
false-culture-negative results. With a very low culture contamina-
tion rate, it is likely that some M. tuberculosis organisms, especially
from paucibacillary specimens, have been killed during decon-
tamination (7). Furthermore, “viability” of bacilli as defined by
FDA positivity (fluorochrome activation by enzymatic activity)
FIG 1 Numbers of included ZN1 sputum specimens with specimen characteristics. ZN1, Ziehl-Neelsen stain-positive sputum smear; MTB1, Mycobacterium
tuberculosis-positive culture; NTM1, nontuberculous mycobacterium-positive culture; ZN scanty1, 1 to 9 bacilli/100 HPF; ZN $ 11, $10 bacilli/100 HPF.
TABLE 1 FDA smear performance, total and by treatment phasea
Specimen type (n)
No. with FDA
result:
% SE
(95% CI)
% SP
(95% CI)
% PPV
(95% CI)
% NPV
(95% CI)
LR1
(95% CI)
LR2
(95% CI)Positive Negative
Total (273b) 83.7 (70.3–92.6) 66.1 (59.5–72.2) 35.0 (26.4–44.4) 94.8 (90.1–97.8) 2.5 (1.9–3.0) 0.2 (0.1–0.5)
C1 41 8
C2 76 148
Delayed responder (194) 82.2 (67.9–91.9) 60.4 (52.1–68.3) 38.5 (28.8–49.0) 91.8 (84.5–96.4) 2.1 (1.6–2.6) 0.3 (0.1–0.5)
C1 37 8
C2 59 90
Suspected failure (79) 100 (39.7–100)c 77.3 (66.2–86.2) 19.9 (0.5–41.9) 100 (93.8–100)c 4.4 (2.9–6.7) 0.0
C1 4 0
C2 17 58
a Abbreviations: C, culture; C1, M. tuberculosis positive; C2, M. tuberculosis negative; SE, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value;
LR1, positive likelihood ratio; LR2, negative likelihood ratio.
b Fifteen specimens were excluded: the FDA smear was not readable for 1 sample, 1 had culture result “contaminated,” and 13 samples were NTM positive.
c One-sided 97.5% confidence interval.
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may not always correspond to bacillus “viability” as defined by
culture (ability to multiply) (6). This may be more pronounced
among specimens derived from early treatment phases. It is of
note that the specific LED system used (480-nm cassette) and
smear reading at 31,000 magnification did not confer a very
strong fluorescent signal. A potent fluorescence signal for FDA
smears can be achieved using the standard LED setup for aura-
mine (450-nm cassette and 510-nm-long pass filter) combined
with reading at 3200 magnification (A. Van Deun, personal com-
munication).
In this second study assessing the FDA method, the perfor-
mance was not accurate enough to propose the FDA smear
method as a stand-alone tool for TB treatment monitoring. How-
ever, in this study population with few confirmed failures, the
good NPV and LR2 may suggest using the method to rule out
treatment failure and avoid an unnecessary second-line regimen.
In programs with limited access to M. tuberculosis culture, the
FDA method may help in identifying cases (FDA positive) requir-
ing culture assessment. Such application needs further evaluation.
Additional evaluation is also needed in populations with higher
proportions of confirmed failures.
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